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Despite all the efforts made over years to study the cancer expression and the metastasis 
event, there is not a clear understanding of its origins and effective treatment. Therefore, 
more specialized and rapid techniques are required for studying cell behaviour under 
different drug-based treatments. Here we present a quantum dot signalling-based cell assay 
carried out in a segmental microfluidic device that allows studying the effect of anti-cancer 
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drugs in cultured cell lines by monitoring phosphatidylserine translocation that occurs in 
early apoptosis. The developed platform combines the automatic generation of a drug 
gradient concentration, allowing exposure of cancer cells to different doses, and the 
immunelabelling of the apoptotic cells using quantum dot reporters. Thereby a complete 
cell-based assay for efficient drug screening is performed showing a clear correlation 
between drug dose and amount of cells undergoing apoptosis. 
 


















Drug discovery is a field of research in constant development due to the need of new 
and improved drugs to treat different kinds of disorders, diseases or illnesses. Up to 
date, several methods for drug development have been reported (Koel and 
Kaljurand, 2006). The development of new strategies to study the effect of specific 
drugs on biological samples are of crucial importance to verify the drug function on 
human cell lines before conducting the clinical trials (Lledo-Fernandez and Banks, 
2011)
,
(Peng and Chiou, 1990). 
One of the most important fields in drug development research is related to cancer 
treatment (Rodwell, 2013)
,
(Suggitt and Bibby, 2005)
,
(Lieberman et al., 2001). Most 
anticancer drugs such as Camptothecin (CAMPT) induce apoptosis (Lin et al., 
2013)
,
(Han et al., 2009), with some common characteristics (endonucleolytic 
cleavage of DNA, chromatin condensation, caspases activity, phospholipids 
translocation, etc.), which can be used to develop different methods for cell 
apoptosis detection by the recognition of a specific apoptotic marker (Sellers and 
Fisher, 1999). Several strategies to detect apoptotic cells have been reported being 
the detection of phosphatydilserine (PS), a phospolipid located in the inner leaflet of 
the plasma membrane (PM) that translocates to the outer one at early stages of 
apoptosis, one of the most common methods currently in use.  
Detection of PS through the specific phospholipid-binding protein Annexin V 
(AnnV) has been widely used for diagnosis (Schutters and Reutelingsperger, 
2010)
,
(Van Tilborg et al., 2010) and as an imaging tool to monitor the apoptotic cell 
death progression when AnnV is conjugated to a fluorescent dye (Andree et al., 
1990)
,
(Vermes et al., 1995). This non-invasive technique for the cell is a good 
 4 
alternative for drug screening assays. However, one of the main problems of AnnV-
based fluorescent probes is the limited photostability of the organic dyes conjugated 
to it and the scarce diversity of commercially available AnnV-conjugated dyes, to 
avoid spectral overlapping. These problems can be solved using Quantum Dots 
(QDs) as fluorescent reporters instead of standard organic dyes (Resch-Genger et al., 
2008).  
QDs are already commercially available due to their high demand given their unique 
optical properties and great potential in diagnostic imaging with particular interest in 
cancer diagnosis (Algar and Krull, 2010).
 
We have already reported the advantages of 
QDs over organic dyes for labelling intracellular structures through double or triple 
immunocytochemistries, showing higher fluorescence intensity, narrower bandwidth 
and higher photostability (Montón et al., 2009) and we have as well demonstrated the 
efficient employment of QDs as labels in microarray technology for either protein 
(Morales-Narváez et al., 2012) (Alzheimer’s disease biomarker screening) or bacteria 
(Morales-Narváez et al., 2013) detection (E. coli detection in a digital like response via 
fluorescence quenching with graphene oxide). Thereby, the use of QDs conjugated 
to AnnV provides a unique candidate to monitor apoptosis in time-lapse imaging due 
to their high photostability (Le Gac et al., 2006). 
QD-based labelling strategies can improve conventional technologies but, 
modifications in the assay platform such as the use of microfluidics would allow the 
development of a cheaper and more efficient method (Vannoy et al., 2011)
 
by down-
scaling the cell environment, making biological interactions more dynamic 
(microflows), and decreasing sample, reagents and time of analysis (Janasek et al., 
2006). 
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Microfluidic devices are basically known as integrative platforms to carry out 
diverse and complex experiments (Whitesides, 2006). Although many researchers 
are proposing highly integrated and sophisticated platforms (Du et al., 2013; Jang et 
al., 2011), the complexity of the experiments for non-experienced personnel can be a 
drawback due to their multiple components. However, the use of modular 
configurations, also called “building blocks” (Hill et al., 2016), brings the 
opportunity to couple different kinds of chips depending on the requirements of each 
experiment in a versatile and simple way, resulting in a large number of 
combinations (Yuen, 2008; Yuen et al., 2009). The main idea is that several 
microfluidic components can be connected in a motherboard to perform a larger 
integrated system (Skafte-Pedersen et al., 2013), or to mimic organs on a chip for 
drug screening under different physiological conditions (Loskill et al., 2015). 
DNA detection (Hsieh et al., 2012; Yazdi et al., 2013), protein immunoassays (Diercks et 
al., 2009; Tekin and Gijs, 2013), and cell-based experiments (Hajba and Guttman, 2014), 
based on microfluidic platforms have been widely reported in the literature. Focusing on 
cell studies using microfluidics, several platforms for cytotoxicity evaluation and drug 
discovery have also been described (El-Ali et al., 2006; Jedrych et al., 2011). However, the 
above mentioned platforms have been used to study drug toxicity in cells by analysing their 
morphology or viability ex-situ mainly using organic dyes, which are not stable and not 
sensitive enough for long-term studies (Kim et al., 2011; Wang et al., 2015). 
Here, we present a more specialized assay in which the translocation of PS to the outer 
leaflet of the plasma membrane in apoptotic cells is specifically labelled by an AnnV-QD 
conjugate, all done within microfluidic modules, giving more insight on the apoptotic 
process. The anticancer drug CAMPT is used as model to induce apoptosis and QDs 
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conjugated to AnnV to reveal the PS translocation in cells undergoing apoptosis upon 
exposition to CAMPT. To achieve the drug test in human carcinoma cells we carry out the 
assay in a segmental microfluidic device in two phases: i) we culture the cells into the chip 
intended for apoptotic cell detection (CELL chip) and then we connect it with the 
concentration gradient generator chip (CGG), previously reported by Jeon et al. (Jeon et al., 
2000) to expose the cells to different CAMPT doses; ii) the cells previously exposed to 
different CAMPT doses are incubated with the AnnV-QD conjugates prepared using a 
mixer chip (MIX). The AnnV-QD labelling performed in a microfluidic platform proves to 
be an effective method to quantify cell apoptosis through specific recognition of PS (Figure 
1B).  
 
2. Results  
Optimisation of the CELL chip 
We established a sterilisation method for the CELL chip, made of glass and 
polydimethylsiloxane (PDMS), and an appropriate number of cells to seed in it to obtain 
optimal results. On the one hand, we checked different methods of sterilisation: i) chips 
filled with 70 % ethanol, emptied immediately after and followed by UV light exposure for 
1 h after removing the ethanol, ii) chips filled with 70 % ethanol and exposed to UV light 
for 1 h, and iii) chips filled with 70 % ethanol until use (no UV light exposure). According 
to our experiments, the sterilisation methods involving UV light exposure resulted in low 
cell attachment and growing, probably due to the creation of free radicals produced by the 
UV-cleavage of the polymer backbone in the PDMS. The presence of free radicals might 
affect the cell growth due to oxidative stress which can modify both cells and cell products 
leading to cell apoptosis, protein modification, cross-linking and precipitation.(V. Lobo, A. 
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Patil, A. Phatak, 2010). Therefore the most suitable method in terms of cell culture growth 
24 h post-seeding was a single-step of filling it with ethanol 70% until use (Supporting 
Information Figure S1). On the other hand, we analysed the number of cells growing in 
each chamber of the sterilised chip (1, 2, or 3 in Figure 1A, i) to ensure that the cells were 
uniformly distributed in the CELL chip. We designed the CELL chip with oval-shaped 
chambers and channel ramifications to obtain a uniform distribution of cells and to avoid a 
possible cell detachment caused by high flow, which is very important for obtaining 
reproducible results during microscope image acquisition (Figure S2). With this design, we 
found no differences in cell number among the chambers (Figure 1A, ii), therefore each 
chamber is considered a replicate in the final assay. In addition, we seeded different number 
of cells in different chips to find the optimal concentration of cells after 24 h incubation 
(data not shown). We chose to seed 120,000 cells per chip to almost reach a cell monolayer 
in the chambers at the moment of inducing the apoptosis (24 h post seeding). 
Optimisation of the CGG chip 
To optimise the performance of the CGG chip we evaluated the flow rate and duration of 
the reagent injection. We simulated the real composition of the solutions to be used in the 
final assay: supplemented cell culture medium (Minimum Essential Medium, MEM) was 
introduced by one of the inlets and a combination of MEM, dimethyl sulfoxide (DMSO, 
CAMPT diluent) and trypan blue (to simulate CAMPT drug and to visualize the mixture) 
was introduced through the other one. To evaluate the gradient of concentrations obtained 
with the CGG chip, we took microscope images in the outlets (Figure 1B, i) and we further 
processed them with ImageJ software to obtain the relative intensities of colour (Supporting 
Information Figure S3) which would be related to a specific solution concentration 
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introduced in the inlets. According to theoretical predictions for such design (Supporting 
Information Figure S4), the relative concentrations in the outlets should be 0, 0.125, 0.5, 
0.875 and 1, corresponding to 0, 2.5, 10, 17.5 and 20 µM of CAMPT. We compared the 
experimental values obtained at different flow rates and times (Supporting Information 
Table 1) with the predicted theoretical values (Figure 1B, ii) and we found that a 10 µL/min 
flow rate during 3 min resulted in the closest to theoretical given concentrations at the end 
of each outlet. The experimental concentrations corresponded to 0, 4, 11, 16 and 20 µM 
respectively. Considering that range a good start point for gradual doses of CAMPT we 
used this setup to test the platform performance for a full drug screening assay. We as well 
carried out repeatability and reproducibility studies by repeating measurements in the same 
chip and in three different chips, respectively (Supporting Information Figure S5) and we 
found negligible differences between measures, thus demonstrating the functionality of the 
CGG chip in generating a gradient of concentrations. 
Optimisation of the MIX chip 
Conjugation of AnnV-biotin with Streptavidin-QDs is performed in the first section 
of the chip (C sector -conjugation-, Figure 2C, i) whereas AnnV-QD is mixed with 
the Ca
2+
 enriched medium for cell incubation in the second section (M sector -
mixing-, Figure 1C, ii). To optimise the performance of the MIX chip we first 
evaluated the C sector by introducing streptavidin-QDs at a concentration of 120 nM 
through inlet 1 (Figure 1C) and AnnV-biotin through inlet 2 (Figure S6, Supporting 
Information). Fluorescence images were taken at certain points (C0, C50, C100 and 
C150 cm) from the beginning of the inlet path of C sector in order to evaluate the 
fluorescence intensity in several Regions of Interest (ROIs) with the aim to calculate 
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the mixing factor which reflects the homogeneity of the solution and thus the best 
conditions to perform the AnnV-QD conjugation. We tested several flow rates and 
injection times (Supporting Information Table 2). We found that a flow rate of 5 
µl/min during 12 min were the optimal parameters to obtain a mixing factor value of 
almost 1 at the end of the C sector of the chip (Figure 1C, i). We also carried out 
repeatability and reproducibility studies for the C sector and we observed negligible 
differences between measurements or chips (Supporting Information Figure S7a).  
We proceeded similarly to evaluate the M sector of the MIX chip (Figure 1C, ii); we 
introduced AnnV binding buffer through inlet 3. We acquired fluorescence images along 
the channel path in M sector (M0, M50, M100 and M150 cm: see, inset images in Figure 
1C, ii) and we determined the mixing factors at each of these points. We found the best 
compromise between the duration of the assay (6 min) and the obtaining of appropriate 
mixing factors at a flow rate of 20 µL/min (Figure 1C, ii). As for the C sector, we evaluated 
repeatability and reproducibility for M sector of the chips and we found no significant 
differences between repeated measurements neither in a same chip nor in different ones 
(See Supporting Information Figure S7b). 
 
Screening the apoptotic effect of CAMPT on human adenocarcinoma cells 
Once the three modules were separately optimised, the suitability of the modular platform 
to carry out a real cell-based assay was demonstrated by performing three sequential steps. 
First, the cells were seeded in 5 different CELL chips and incubated overnight to proliferate 
in a CO2 incubator. Second, after incubation each of the 5 CELL chips was connected to an 
outlet of the CGG chip followed by introduction of 20 µM CAMPT (diluted in DMSO) and 
1X MEM through the two different inlets of the CGG chip (Figure 2A). As a result, each 
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CELL chip was exposed to a different dose of CAMPT ranging from 0 to 20 µM using 
optimal flow rates and times (Table 1) (Figure 2A ).  
Then CELL chips were disconnected from the CGG chip and placed in the incubator for 4 h 
in order to allow the induction of apoptosis in the cell cultures. The third step of the assay 
was to label positive-apoptosis cells with AnnV-QD probes (Figure 2B). To achieve this, 
biotinylated AnnV and streptavidin-QD were introduced through the two inlets (1 and 2) of 
the C sector of the MIX chip followed by the introduction of AnnV binding buffer through 
the third inlet (3) located in the M sector of the MIX chip in order to dilute the AnnV-QD 
probe in the appropriate binding buffer. We sequentially connected the MIX chip to each of 
the CELL chips in order to let the probe interact with the cells. We incubated the CELL 
chips with the AnnV-QD probe solution for 30 min in order to label the translocated PS in 
apoptotic cells, followed by a washing step of supplemented MEM for 7 min at a flow rate 
of 4 µL/min to remove unbound AnnV-QD. Each CELL chip exposed to a different dose of 
CAMPT was analysed by fluorescence microscopy in order to determine the percentage of 
apoptotic cells. Three areas per chamber for each chip were selected to acquire bright field 
images (Figure 3A, i) and fluorescence images (Figure 3A, ii) for further analysis.  
The images were processed to establish the apoptosis ratio for each CAMPT dose exposure 
(0, 4, 11, 16 and 20 µM). As expected, the higher the concentration of CAMPT used to 
induce apoptosis the higher the number of cells labelled with AnnV-QD (apoptotic cells). 
In order to determine the number of apoptotic cells upon different drug concentrations, we 
calculated the ratio between the number of positive cells (apoptotic cells labelled with 
AnnV-QD) upon the total number of cells (apoptotic and non-apoptotic cells). Figure 3B 
shows the dose-response curve of cell cultures exposed to specific doses of CAMPT (0; 4; 
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11; 16; and 20 µM) obtained from the image analysis. Each point represents the mean value 
obtained from the quantification of three different chambers and the error bars show the 
standard deviation between those measurements. A certain amount of apoptosis (10-20%) 
was found for chips incubated with 0 µM CAMPT corresponding to the basal level of 
apoptosis within the cell culture. Two replicates of this experiment were carried out in 
different days and results obtained were similar (Supporting Information Figure S8) 
showing the good reproducibility of the method.  
3. Discussion 
The results shown here indicate an appropriate correlation between the dose of CAMPT 
and the relative number of apoptotic cells labelled with AnnV-QD probes. As a proof-of-
concept, we have demonstrated the applicability of the platform to carry out cell-based 
assays for drug screening with a low standard deviation (from 3 to 8 %). Considering the 
factors that a cell based assay for drug development should feature, such as sensitivity of 
detection and reagent stability (Riss, 2005), an important advantage of the developed 
system is the use of QD instead of fluorescent dyes to reveal apoptosis. QDs are one of the 
most robust bioassay labels to carry out long optimisations and quantifications which 
require high sensitivity and stability of signal that other labels such as dyes cannot provide. 
Their compatibility in biological media, long-term stability and resistance to 
photobleaching make them ideal tools to monitor real time events, as we have shown, 
obtaining sensitive and reliable measures of apoptosis. Moreover, the versatility of QDs 
offers the possibility to evolve this work in different ways to fulfil a specific goal 
depending on the bioanalytical/bioassay scenario. For instance, CELL chips can be 
fabricated with integrated electrodes and electrochemical assays can be performed using the 
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same QD-based probes thanks to the use of redox properties of QDs (Medina-Sánchez et 
al., 2015). Proof of that is the electrochemical-based microfluidic platform we have 
reported as an efficient alternative to detect very low levels of a relevant biomarker for 
diagnostics (Medina-Sánchez et al., 2014).
 
Therefore, an important advantage of the 
presented QD mediated monitoring is the possibility to be also used in a dual 
optical/electrical detection (given the QD properties) that may allow a fast quantitative 
monitoring of the apoptosis process induced by a chemical stimulus. In this way the effect 
of certain doses of an anticancer drug would be detected electrochemically in-chip as it has 
been recently demonstrated in batch mode (Montón et al., 2015).   
The developed platform combines the versatility of QDs with the advantages of modular 
microfluidics: each chip can be modified, replaced by another one or removed to obtain a 
suitable system for each new application. The obtained results demonstrate that the 
combination of QDs with a modular microfluidic platform gives rise to a robust and 
sensitive cell assay for drug discovery applications. In addition this leads to significant both 
time and reagent saving due to the in-chip preparation of the reagents (drug doses, labelling 
probe conjugation) and due to the small volumes required to perform the assay. For 
example, experiments performed in the presented modular microfluidic system use 4 times 
less volume of CAMPT stock solution (1 µL of stock solution is sufficient to prepare all 
working solutions in CGG chip) comparing with common techniques based on multiple 
well plates. Similarly, smaller volumes of QDs, cells suspensions and buffers are used in 
microfluidic chips than in plate-based assays. Moreover, this cell-based assay performed in 
microfluidic chips is characterized by a shorter duration of the experiment (at least 40% 
using our platform) and by fewer manual steps that may introduce variability in the system. 
For instance, if a multiple well plate is necessary to carry out the same or a similar assay 
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several additional steps can be applied. For example, the conjugation protocol would 
include various washing and separation steps, while in microfluidics this step is reduced 
and simplified by flowing a buffer through the channel, reducing time and avoiding 
possible damage of the cell culture. Regarding the preparation of CAMPT doses, these 
should be manually and individually prepared in the case of a multiple well plate based 
assay. The use of the proposed microfluidic chip drastically reduces errors in manipulation 
and cell contamination in addition of offering a robust and easy to use system even for use 
out of a specialized laboratory and even by non-professional users. 
The novelty of this work relies not only on the use of an optimised modular platform to 
carry out a full drug screening assay without manual steps (from drug doses and labelling to 
apoptosis detection) but also on the high accuracy of the assay as shown in the 
reproducibility of the results. The functionalities of the chips we used in this work have 
been already described and similar geometries have been used separately for different 
purposes. However their combination to carry out a complex assay in a simple, fast and 
cost-effective manner has not been reported until now. So far, reported lab-on-chip 
platforms for drug screening or imaging purposes have been used in disconnected steps so 
either drug concentration preparation, labelling or both of them have been done manually 
(Kim et al., 2011; Zhao et al., 2013). Moreover, the versatility of the modular platform we 
presented will allow a number of different types of assays to be performed, other than drug 







In this work, we presented a versatile modular microfluidic platform that performs optical 
drug screening assays. As test bed, we focused on the detection of apoptosis in cancer cells, 
induced by the presence of the pro-apoptotic drug camptothecin. In particular, we combined 
geometrically different chips to achieve three main functionalities: the generation of a drug 
gradient concentration, the functionalisation of QDs with AnnV, and the optical detection 
of apoptotic HeLa cells. Our platform successfully showed a clear correlation between drug 
dose and amount of cells undergoing apoptosis. Compared to traditional methods used for 
drug screening, our platform offers improved ease of use (decreasing the number of manual 
steps), speed (reducing the overall assay time by 40%), miniaturization/portability and 
versatility. Considering that this QDs/modular microfluidic bioassay platform can be easily 
adapted to specific requirements by redesigning the geometries of the chips, the probes or 
the target cells, we believe that our system can meet the needs of laboratories looking for a 
versatile methodology to evaluate new drugs during preclinical stages. 
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Figure 1.  Segmental chips optimisation. (A) CELL chip optimisation: i) schematic of the 
CELL chip with the three chambers where cells are seeded for analysis, and ii) cells 
uniformly distributed in the three chambers of the same chip 24 h post-seeding. (B) 
Optimisation of concentration gradient generator: i) schematic of the CGG chip with the 
corresponding outlet images (optical images of the trypan blue dilutions at the end of the 
channel of each outlet), and ii) comparison between theoretical and optimal experimental 
concentration data resulted from the obtained solutions at the outlets (0, 2.5, 10, 17.5, 20 
µM and 0, 4, 11, 16, 20 µM, respectively), and (C) optimisation of the MIX chip: i) graph 
of mixing factors obtained from images taken at C0, C50, C100 and C150 cm of the 
channel path in the C sector (conjugation of AnnV and QDs), and ii) Graph of mixing 
factors calculated along the M sector of the chip from images taken at M0, M50, M100 and 
M150 cm, where conjugated AnnV-QDs are mixed with the Ca
2+
 enriched binding buffer. 
 
Figure 2.  Modular microfluidic platform for apoptosis monitoring. (A) Human 
carcinoma cells (HeLa) are cultured in the CELL chip composed by three identical 
chambers. Cells growing in the CELL chip are exposed to different CAMPT doses obtained 
through the concentration gradient generator chip (CGG). In this stage, cells will start 
translocation the PS to the outer leaflet of the plasma membrane. (B) In a second step a 
mixer chip (MIX) with two identical areas is in charge, first, of the conjugation of 
biotinylated AnnV with streptavidin-QD and, second, the mixture of AnnV-QD conjugates 
with the binding buffer containing the Ca
2+
 required for the specific binding with the 
translocated PS. The MIX chip is then connected to the CELL chip in order to incubate 
cells with the probe and to label the apoptotic cells. Photographs of the set of chips used in 
the two-stage assay are shown next to the schematics: (A) fluidic interconnection between 
the CGG chip where the CAMPT doses are generated and the respective CELL chips where 
cells are grown, (B) fluidic interconnection of the MIX chip, where the AnnV-QD 
conjugation takes place, with the CELL chips exposed, in the previous step (A), to different 
doses of CAMPT. Labelling is done in this step. 
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Figure 3. Apoptosis induction by different CAMPT doses. (A) Example of images 
obtained from the chips after incubation with CAMPT and labelling with AnnV-QD: i) 
typical bright field image of a selected area of the chamber, ii) fluorescence image of the 
same selected area overlapped with the bright field image. (B) Graph showing the dose-
response curve corresponding to the ratio of apoptotic cells/total cells (QD-labelled 
cells/total number of cells) in relation to the CAMPT concentration they were incubated 
with. Standard deviation bars show the repeatability results between the three different 
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- A modular microfluidic platform combined with AnnV/QD probes is designed to 
perform drug screening assay. 
- Human carcinoma cell lines are used as a target and apoptosis is detected upon 
an anti-cancer drug exposure. 
- Our system shows dose-response correlation being easier to use, faster and 
versatile than traditional drug screening methods. 
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